|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This site is Private and is used only for training new Angel Editors, Bloggers & Columnists! | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
5/12/13{THIS IS A PERFECT NEWS POST BECAUSE IT HAS A PHOTO & CATCHY HEADLINE & INCLUDES THE WORDS: Multiple Sclerosis} UK close to approving cannabis spray for Mulitple Sclerosis Patients(Posted By: Josi Creek) (Reuters) - A pioneering -- but much delayed -- cannabis-based medicine for multiple sclerosis is now on track to win regulatory approval in Britain and Spain, its maker said on Thursday. GW Pharmaceuticals said regulators in both countries had concluded there were no major quality, safety or efficacy issues remaining to be resolved. Talks are now focused on points of clarification related to the patient information leaflet. Approval of the dug Sativex in Britain and Spain will be a landmark for the British drugmaker, whose shares jumped more than 12 percent to a four-year high on the news by 0940 GMT (5:40 a.m. ET). The medicine, which is sprayed under the tongue, is to be marketed in Britain by Germany's Bayer and in the rest of Europe by Spain's Almirall. Read the full story here. |
Post a Comment